玻璃体内单次注射贝伐单抗（阿瓦斯汀）与玻璃体内单次注射曲安奈德（肯纳科特）治疗难治性非感染性葡萄膜炎性囊样黄斑水肿的短期疗效比较。

Short-term results of a single intravitreal bevacizumab (avastin) injection versus a single intravitreal triamcinolone acetonide (kenacort) injection for the management of refractory noninfectious uveitic cystoid macular edema.

机构信息

Retina and Vitreous Service, Clínica Oftalmológica Centro Caracas, Caracas, Venezuela.

出版信息

Ocul Immunol Inflamm. 2009 Nov-Dec;17(6):423-30. doi: 10.3109/09273940903221610.

DOI:10.3109/09273940903221610

PMID:20001264

Abstract

PURPOSE

To report the short-term results of a single intravitreal injection of bevacizumab (IVB) versus a single intravitreal injection of triamcinolone acetonide (IVT) to treat refractory noninfectious uveitic cystoid macular edema (CME).

METHODS

Twenty-eight consecutive patients (36 eyes) were retrospectively included. Patients received either 2.5 mg of IVB (16 eyes) or 4 mg of IVT (20 eyes).

RESULTS

In the IVT group, baseline best-corrected visual acuity (BCVA) was logMAR 1.1 +/- 0.2, and improved to 0.7 +/- 0.3 (p < .001) at 6 months. In the IVB group, baseline BCVA was logMAR of 1.2 +/- 0.4 and improved to 0.8 +/- 0.4 at 6 months (p = .031). At 6 months, central macular thickness (CMT) in the IVT group improved from 454.8 +/- 238.9 microm to 296 +/- 134.4 microm (p < .0001).

CONCLUSION

A single IVT injection improves BCVA and reduces CMT more effectively than IVB in refractory noninfectious uveitic CME at 6 months.

摘要

目的

报告单次玻璃体内注射贝伐单抗（IVB）与单次玻璃体内注射曲安奈德（IVT）治疗难治性非感染性葡萄膜炎性囊样黄斑水肿（CME）的短期疗效。

方法

回顾性纳入 28 例（36 只眼）连续患者。患者分别接受 2.5mg IVB（16 只眼）或 4mg IVT（20 只眼）治疗。

结果

在 IVT 组，基线最佳矫正视力（BCVA）为 logMAR1.1 +/- 0.2，并在 6 个月时改善至 0.7 +/- 0.3（p <.001）。在 IVB 组，基线 BCVA 为 logMAR1.2 +/- 0.4，在 6 个月时改善至 0.8 +/- 0.4（p =.031）。在 6 个月时，IVT 组的中心黄斑厚度（CMT）从 454.8 +/- 238.9μm 改善至 296 +/- 134.4μm（p <.0001）。